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3	 	 	 	 Live as if you were going to die tomorrow,
    Learn as if you were going to live forever.
     Mahatma Gandhi
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7AbstrACt
Colorectal cancer (CRC) is a common disease and a major cause of cancer related death 
globally. Prognosis is rather good in early stages but worse in cases with disseminated 
disease. There is a constant need of developing all treatment modalities, which also has 
been done over the last decades. There are needs to find predictive markers in order to 
assess who will and who will not benefit of chemotherapy, just as there are needs to 
develop drugs targeting novel pathways and proteins prevalent in primary tumors and 
metastases. CYP2W1 is a member of the cytochrome P450 superfamily of enzymes 
with unknown physiological functions but found to have the capacity to metabolize both 
carcinogens and various other xenobiotic substances. It is expressed in fetal rat colonic 
tissue and in human colorectal tumors, but not to our knowledge in any adult normal 
human tissue. CYP2W1 expression, both mRNA and protein, has previously been studied 
in a material consisting of about 50 colorectal tumor samples. 
We wanted to investigate the extent of CYP2W1 expression in a larger tumor material 
using immunohistochemistry. We found it also interesting to see if CYP2W1 expression 
affects prognosis. Another aim of the thesis was to assess the association between 
polymorphism in the CYP2W1 gene and risk to develop CRC. A last aim was to evaluate 
the CYP2W1 expression in metastases.
For the first aim, we used three different patient cohorts, two of which were derived 
from a randomized Nordic trial aiming to compare no adjuvant versus adjuvant treatment 
in patients with stage II and III CRC. These cohorts consisted of 162 and 235 patients 
respectively. The third patient cohort consisted of 96 patients being resected for liver 
metastases from CRC. All tumor manifestations in these patients were investigated with 
immunohistochemistry, addressing both the first and the last aim, and the findings indicate 
that CYP2W1 is expressed at high levels in between 26-36% of the primary tumors. It 
is expressed in about one third of lymph node metastases and almost half of the liver 
metastases.  
We performed two investigations regarding CYP2W1 as a prognostic factor using the 
two cohorts from the Nordic study (n=162 and n=235). In the first study, high CYP2W1 
expression was of independent prognostic value for poor survival together with stage. 
In the second study aiming to reproduce this, the result was not as clear-cut, CYP2W1 
was of prognostic value only in multivariate analysis but not in univariate analysis. 
In the subgroup of patients with stage III CRC (n=132), CYP2W1 expression was of 
independent prognostic value.
The third aim was addressed using a material of DNA from individuals in a large case-
control study aiming to investigate various polymorphisms and their relation to CRC 
risk. DNA from 1785 CRC patients and 1761 control subject was analyzed regarding 
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three CYP2W1 variants. We also experimentally assessed enzymatic activity of the gene 
products of the variants studied. No difference was seen, neither in CRC risk between 
cases and controls, nor in enzymatic activity between the three variant proteins. 
In conclusion, CYP2W1 seems to be expressed in about one third of primary CRC and 
half of the liver metastases. The association with prognosis in CRC requires further 
studies to be elucidated. Genetic polymorphism in the CYP2W1 gene does not seem to 
have any impact on CRC risk. 
The tumor specific expression of a catalytic enzyme in CRC and metastases is interesting 
in the aspect of future targeted anti-cancer therapies.
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IHC Immunohistochemistry 
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95% CI 95% Confidence interval
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thesis At A GLAnCe 
Question Patients and methods Results Conclusion
I What is the 
expression pattern 
of CYP2W1 like in 
colorectal cancer? 
Is CYP2W1 
expression 
associated with 
survival? 
162 patients with stage 
II and III colorectal 
cancer (117 colon 
and 45 rectum) 
treated between 1991 
and 1996. Tumor 
samples analyzed with 
immunohistochemistry.
Strong expression 
of CYP2W1 was 
seen in 36% of 
patients. Strong 
expression correlated 
independently with 
poor 5-year survival.
CYP2W1 is 
strongly expressed 
in about one 
third of colorectal 
tumors, and it 
seems to be an 
independent 
prognostic factor.
II Are the results 
of study I 
reproducible in 
another cohort 
of patients? 
Is CYP2W1 
expression similar 
in two different 
samples from the 
same tumor?
235 patients with stage 
II and III colon cancer 
treated between 1991 
and 1996. Tumor 
samples analyzed with 
immunohistochemistry.
Strong expression 
of CYP2W1 was 
detected in 30% of 
tumor samples. There 
was good correlation 
between two slices 
from the same 
tumor. Independent 
prognostic value 
only in multivariate 
analysis, not in 
univariate analysis.
CYP2W1 is 
expressed in 
about one third 
of colorectal 
tumors with similar 
expression in 
different slices of 
the same tumor. 
The question 
of prognostic 
significance 
needs further 
investigation.
III Is polymorphism 
in the CYP2W1 
gene associated 
with altered risk 
of developing 
colorectal cancer? 
Does genetic 
polymorphism 
alter the function 
of the enzyme?
DNA from 1785 patients 
and 1761 control 
subjects was analyzed 
with PCR regarding 
polymorphisms 
CYP2W1*2 and 
CYP2W1*6.Genetic 
constructs of these 
polymorphisms were 
inserted into SW480 
colon cancer cell line 
and enzymatic activity of 
the gene products were 
assessed.  
No difference was 
seen in genotype 
between cases and 
controls. No difference 
in functional activity 
was detected between 
the variant enzymes.
Genetic 
polymorphism in 
the CYP2W1 gene 
does not alter the 
functional activity 
of the enzyme. 
Nor does it affect 
risk to develop 
colorectal cancer.
IV Does the 
expression of 
CYP2W1 change 
in the individual 
patient between 
primary tumor, 
lymph node 
metastases and 
liver metastases? 
What is the 
expression pattern 
of CYP2W1 like in 
liver metastases?
Material from primary 
colorectal tumors, lymph 
node metastases and 
liver metastases from 96 
patients, analyzed with 
immunohistochemistry.
High CYP2W1 
expression was 
detected in 26% 
of primary tumors, 
31% of lymph 
node metastases 
and in 48% of liver 
metastases. The 
difference between 
primary tumors and 
liver metastases was 
statistically significant.
The amount of 
tumors with high 
expression of 
CYP2W1 seems 
to increase 
between primary 
tumors and liver 
metastases. This 
finding needs 
validation with 
another method.
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introduCtion
Colorectal cancer – epidemiology
Colorectal cancer (CRC) is a significant global health problem being the third most 
common cancer in men and the second most common cancer in women, and causing about 
600.000 deaths per year (1).  There is a great variation in incidence between different 
countries with the highest rates seen in Australia/New Zealand and Western Europe, and 
the lowest in Africa and South-Central Asia (2). In Sweden, 3256 men and 2924 women 
were diagnosed with CRC in 2009 (3).
Mortality rates in CRC have declined in Sweden and in other western countries as well, 
during the past decades. This is most probably due to improved surgical techniques, more 
potent chemotherapeutics and the development of techniques to resect metastatic disease, 
but also to early detection of the tumor (4-6). In the United States, the falling incidence 
rates and decreasing mortality rates are believed to be strongly related to early detection 
in screening programs (1, 2). In Sweden, an organized screening program started in the 
Stockholm-Gotland region in 2008, and a national prospective study run by the regional 
centers of epidemiological oncology is planned to start in autumn 2013 in order to evaluate 
the effect of population based CRC screening in Sweden.
In spite of all improvements in treatment regimens and early detection programs, CRC 
remains to be a major cause of cancer related deaths with a global mortality of 600.000 
deaths 2008 (1).
Staging and survival
Survival in CRC is highly dependent on stage at diagnosis of the tumor. In Sweden, the 
staging procedure involves endoscopy of the colon and rectum, computed tomography of 
the thorax and abdomen, in rectal cancer also an investigation with magnetic resonance 
imaging, and may in selected cases include a positron emission tomography examination. 
All information from the examinations is put together to assign a stage according to the 
Tumor – Node – Metastasis (TNM) classification system. This TNM stage can be translated 
into a simplified stage where stages I and II means tumor growth in the organ of origin 
only, stage III means spread to regional lymph nodes and stage IV means distant spread 
to other organs. After the examinations, all patients are discussed in a multi-disciplinary 
team conference where the final decision on treatment is made.
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In a recent study of all Swedish patients diagnosed with CRC between 2000 and 2007, 
47% were stages I or II, almost 30% were stage III and 23% were stage IV (5). Liver 
metastases are present in 15-20% of CRC patients at time for diagnosis, and approximately 
another 10-30% will develop liver metastases during the following years, according to a 
couple of fairly recent, population based studies (7, 8).
A recently published national follow-up of five-year survival after treatment for CRC in 
Sweden shows survival rates in stage I of 90-100%, stage II of 75-90%, stage III of 45-
60%, and stage IV of about 10% (9, 10).
About 20% of the patients with liver metastases from CRC are eligible for liver resections 
(11). Complete resection of all metastases in combination with modern chemotherapy 
radically improves survival in those patients with five-year survival rates reaching as high 
as 45-50% (11-14). 
Treatment of CRC – a task for the multidisciplinary team
Survival in CRC has increased due to improvements in all treatment modalities. In 
order to cure the patient, the tumor must be completely removed along with its regional 
lymphatic drainage and blood vessel supply. In addition to that, large or locally advanced 
tumors must be shrunken to resectable size using neoadjuvant treatment which may be 
radiotherapy, chemotherapy or a combination. In addition to that, suspected microscopic 
spread must be treated with chemotherapy. 
Survival in both colon and rectal cancer is significantly better when applying the above 
mentioned surgical principles developed by Heald in 1979 and Hoheberger in the late 1990s 
(15-17). Heald developed the total mesorectal excision method in rectal cancer surgery 
and Hohenberger suggested a similar approach in colonic cancer surgery. Evaluations of 
these methods have supported the view that an intact mesorectal or mesocolic fascia is 
of great importance for survival outcome. With this complete mesorectal or mesocolic 
removal follows the removal of primarily draining lymph nodes which is also important 
for outcome. The increasing awareness of risk for intraoperative tumor spread also has 
improved survival by developing a more cautious technique in cancer surgery	where the 
tumor should ideally be covered with surrounding tissue, and care must be taken not to 
damage this tissue  (18-20).
Preoperative radiation therapy has led to better survival in rectal cancer (21-23). 
Chemotherapy is used preoperatively in locally advanced CRC, and postoperatively in 
stage III colonic cancer or stage II with certain risk factors. This also has contributed to the 
improved outcome (24-26). Regarding metastatic CRC, stage IV, survival has  improved 
because of both the development of more efficient chemotherapeutic agents and targeted 
treatments with for example antibodies (27), and the increasing use of resections for 
localized metastases in e.g. liver, as mentioned above. 
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This complex picture with many different treatment modalities tailored differently to 
different patients, makes the multidisciplinary team the central hub in the treatment 
planning and implementation for CRC patients. There is an increasing amount of evidence 
favoring this way of working with cancer patients (28). 
In spite of all the good progress being made in the treatment of CRC, there is always 
a need for new treatment options, not least because of the side effects associated with 
radical surgery, radiation and chemotherapy, but also because of development of tumor 
cell clones resistant to chemotherapy. In stage IV CRC patients, only about 20% are 
eligible for resection of the metastases, the remaining 80% would also benefit from 
having a larger number of available treatment options. There is also a need to find ways 
to identify both patients who will and those who will not benefit of chemotherapy and 
antibody based biological treatments. 
CRC risk – inherited factors
The pathogenesis of CRC is believed to be multifactorial in most cases, but there 
are a couple of well described inherited syndromes which almost inevitably result in 
CRC: hereditary non polyposis colon cancer (HNPCC or Lynch Syndrome), familial 
adenomatous polyposis (FAP) and the rarest form hamartomatous polyposis syndromes. 
They account for only about 4% of all CRC cases altogether (29, 30). 
Between 10-30% of patients with CRC seem to have a familial clustering where more 
complex genetic interactions are important. In a Swedish population based study from 
the Västmanland region, 11% of CRC patients had at least one first degree relative with 
CRC (31). Twin studies have also been made in order to evaluate the contribution of 
hereditary factors to what is often referred to as sporadic CRC. In a Scandinavian twin 
study, Lichtenstein et al estimated that 35% of the CRC risk is due to heritable factors 
while 60% is attributed to shared environmental factors and 5% non-shared environmental 
factors(32).
The majority of cases – 70-80%- are believed to be caused mainly by environmental 
factors. This hypothesis is supported by migration studies where for instance Japanese 
immigrants to the United States have been found to develop a more western like disease 
pattern, including CRC (33). There might also be cases where low penetrance genes are 
more or less important contributors to the development of CRC by their way of interacting 
differently to environmental factors. Support for this view came initially from genome-
wide association studies (GWAS) where DNA from CRC cases and healthy controls have 
been analyzed, millions of genes are scanned, in order to find differences – risk loci 
– between the cases and controls. This has generated new hypotheses as to what other 
genes might be involved in CRC development (34). The benefit of this method is that it 
gives the possibility to explore thousands of new loci without a prior knowledge of the 
action of the corresponding gene products, a great method to discover genes previously 
Introduction
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unknown that can be further investigated. A problem has been lack of reproducibility 
(35). Also, the power of GWAS studies are lowered due to low risk estimates for each 
locus, with most odds ratios (OR) in the range 1.12-1.20. The power is even further 
lowered because of multiple testing, necessitating a lower p-value to ensure statistical 
significance. Thus, sample size should ideally be at least 10.000 individuals, and the level 
of statistical significance must also be more strictly defined to less than 0.00001. (34). 
Many such low risk alleles are thought to interact in the same individual, in a particular 
environment, and eventually cause cancer.  
High penetrance genes
FAP is a rare disorder caused by a germ line mutation in the APC gene (adenomatous 
polyposis coli) on chromosome 5q21-q22. Roughly 8000 different mutations are known 
in this gene with some variations in phenotype but all associated with CRC (36). 
Approximately one in 7000 CRC patients has FAP (37).  The patients with FAP typically 
develop adenomas of the colon already in their teens and the disease then progresses 
with malignant transformation by age 40. They may also develop polyps and cancer in 
the upper gastrointestinal tract.	 These individuals should be monitored in endoscopic 
surveillance programs with annual endoscopies and be offered prophylactic surgery when 
the amount of polyps is too large for endoscopic removal (30).  
HNPCC is a more common cause of CRC than FAP, about one in 300 CRC patients 
is a carrier of a HNPCC associated mutation (37). This condition is caused by a germ 
line mutation in any of the mismatch repair genes, MLH1, MSH2, MSH6 and PMS2. 
The mismatch repair genes are coding for proteins responsible for correcting errors 
occurring during DNA replication. A defect mismatch repair system results in defect DNA 
replication with increased insertion of wrong DNA bases, thus accelerating the amount 
of genome wide point mutations. If such an event occurs in an important coding area of 
the DNA, it will affect protein function. This is deleterious especially if it involves a gene 
with growth- or differentiation regulation functions, and may then promote malignant 
transformation (38). Among the target genes for the mismatch repair system, many do 
have important functions like cell signal transduction (TGFBR2, AXIN2, IGFR2) or 
apoptosis (BAX, PTEN, CASP5) that are frequently mutated in mismatch repair deficient 
tumors (39). Patients with HNPCC typically also have a family history of CRC. They are 
affected with CRC at an early age, 40-50 years, and approximately 70% of the tumors are 
proximal to the left colonic flexure. The adenoma-carcinoma progression time is observed 
to be shorter in HNPCC associated CRC than in sporadic cases. Patients with HNPCC 
also have an increased risk of developing other cancers, most commonly cancer of the 
uterine endometrium, ovary and the upper gastrointestinal tract (40-42). Patients with 
HNPCC should also be monitored in a surveillance program which includes colonoscopy, 
gynecological examination, transvaginal sonography and endometrial biopsy (30).
MUTYH (mutY homologue) was really the first high penetrant recessive CRC associated 
gene to be described. The phenotype is usually difficult to distinguish from a mild form of 
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FAP. The etiology is a biallelic germ line mutation in the MUTYH gene, resulting in other 
mutations, commonly in the APC and KRAS genes (43).
There are other high penetrance genes causing very rare forms of inherited CRC. These 
syndromes are grouped together under the name Hamartomatous syndromes and include 
Peutz-Jegher syndrome, Juvenile Polyposis syndrome, Cowden syndrome and Gorlin 
syndrome. The genes that are mutated in these disorders are STK11, SMAD4, BMPR1A, 
PTEN and PTCH respectively (36).
Many of the high penetrance genes are mutated in the tumor itself in sporadic cancers, 
i.e where no germ line mutation is present. They are in some cases, like the APC gene, 
crucial steps in the adenoma – carcinoma progression. This will be discussed further in a 
section below.
Low penetrance genes
The above mentioned high penetrance genes are mutated at a low frequency in the 
population but frequently cause cancer. The genetic contribution to the majority of CRC 
cases are by some authors believed to be attributed to interactions between polymorphisms 
in low penetrance genes and various environmental factors, many studies being conducted 
according to the hypothesis “common allele-common disease” (44). 
The GWAS studies conducted have generated new plausible candidate genes, but also 
genes already known to be involved in the development of CRC, like for instance the 
mismatch repair genes or the APC gene, have been explored regarding single nucleotide 
polymorphisms (SNPs) and risk for CRC (45, 46). Other genes of such interest have been 
TGFBR1A, MUTYH, EGFR, HER2, Src, MTHFR, NAT1, NAT2, GSTT1, GSTM1 and 
TP53 (47-52). In many cases, the first study has been promising but the positive results 
have not been possible to reproduce (35).  A recent review by Dong et al has addressed 
the problem of false positive report in large candidate gene association studies reviewing 
161 studies of a sample size of more than 500 subjects each, encompassing 18 cancer sites 
and 99 different genes (53). They came to the conclusion that associations with a prior 
probability of 0.001 and statistical power to detect an OR of 1.5 were less likely to be false 
positive, which was the case in 13 of the 99 genes. Among these, deletion of the GSTT1 
gene was associated with an increased risk for CRC and GSTM1 with bladder cancer. 
These genes are coding for glutathione S-transferases involved in the phase II metabolism 
of toxic xenobiotics and endobiotics. No other genes associated with CRC were among 
those 13. The authors also stress the fact that a good biological hypothesis based on 
previous experimental research or in silico searches strengthens a proven association (53). 
The problem of identifying low risk genes can be even more complicated. There are data 
supporting that the transforming growth factor β receptor 1 (TGFBR1)  polymorphism 
*6A, claimed to be associated with CRC risk in some studies (47) but not in others (49), 
is part of a haplotype associated with cancer risk (54). This means that the polymorphism 
is inherited together with another sequence of the genome that may have a stronger 
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association to cancer risk, and that haplotypes must be taken into account when identifying 
risk loci.
There are probably more genes, with common or rare polymorphisms, that could be 
associated with CRC risk, but larger studies and meta-analyses have to be conducted in 
order to get reliable results. There may also be epigenetic variability explaining some of 
the risk. Epigenetic factors refer to molecules and events affecting DNA transcription. 
Basic cancer epigenetics will be discussed in a section below. An example of epigenetic 
variability affecting cancer risk is for instance polymorphism in genes coding for micro 
RNAs (miRNAs) (44, 55).    
CRC risk – environmental factors
The lifestyle factors most often discussed in connection with CRC are physical activity, 
diet, smoking, alcohol and sex steroid hormones. Another issue of increasing interest is 
that of chemoprevention, especially cyclooxygenase inhibitors, vitamin D and folic acid. 
In the section below, physical activity and diet will be discussed.
Physical activity
There are investigations, many of them rather old, stating that exercise is protective to 
CRC and that a sedentary life style is associated with a higher risk of CRC (56-58). 
There are some weaknesses in the studies, reflecting the difficulties of conducting 
such investigations, e.g self-reported physical activity as a reliable parameter and the 
problematic issue of separating the effect of physical activity from that of body-mass 
index (BMI) and dietary factors. In spite of this, with large sample sizes and the use of 
adequate epidemiological statistical methods, physical activity seems to have a protective 
effect in itself and in interaction with other life style related factors. Martinez et al 
published results from the United States Nurse’s Health study, a large prospective study 
that involved 88751 women age between 34 - 59 years at inclusion. They report a risk 
reduction of almost 50% in women who were physically active and an increased CRC 
risk (OR 1.45,[95% CI 1.02-2.07]) in women with BMI > 29(56). A Norwegian study 
found similar results in men (58). In the study by Slattery et al, the protective effect of a 
healthy diet was greater in the group with a sedentary life style compared with the group 
reporting a higher extent of physical activity (57). The postulated mechanisms behind 
these findings  involve a diverse spectrum of pathways: altered immune function, changes 
in prostaglandin and insulin levels, altered insulin like growth factor 1 (IGF-1) levels and 
bile acid secretion pattern (59). 
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Diet
The studies addressing dietary factors and CRC risk are many and to some extent 
contradictory (60, 61). A good example to this is Willett et al, who also published results 
from the United States Nurse’s Health study. After 10 years follow-up, 150 women had 
developed CRC, and after adjustment for total energy intake, animal fat consumption was 
associated with increased risk for CRC (OR 1.89, [95% CI 1.13-3.15]), and daily intake 
of red meat (beef, pork, lamb) was also associated with CRC risk (OR 2.49, [95% CI 
1.24-5.03]) compared with women eating meat only once per month. Supported by these 
data, the authors suggested that people should be recommended to eat fish and chicken 
instead of red meat (61). Ten years later, the same author, supported by new larger cohort 
studies, meta-analyses and longer follow-up time, blames the CRC risk increase seen 
in Western countries mainly on high total energy intake rather than the consumption of 
specific nutrients like fat (60).
Consumption of red meat was associated with a doubled risk for CRC in the Nurse’s Health 
study (see above), and this association has been studied in many other investigations 
during at least the past three decades, with conflicting results. One such study that has been 
often cited, is a large cohort study of 148.610 patients followed from 1982 and published 
in JAMA 2005 (62). The persons included in the study answered detailed questionnaires 
about life style factors and diet, one in 1982 and one ten years later. During follow-up 
until 2001, 1667 CRCs were diagnosed in the study population. Individuals reporting red 
meat consumption within the highest tertile both in 1982 and 1992, had a higher risk to 
develop CRC compared with those in the lowest tertile (RR 1.50, [95% CI 1.04-2.17]) 
(62) The conclusion was that long term consumption of meat led to higher CRC risk. 
The question whether or not consumption of red meat causes cancer cannot be addressed 
through randomized controlled trials, the golden standard when exploring the association 
of exposure with a certain outcome. The large bulk of studies published on this issue have 
varied a lot regarding study design, definitions of various types of meat, definitions of 
amounts of meat consumed as well as methods to assess it. The range of meat consumption 
in the study population has also varied, and also the different cultural context. Meat 
consumption varies immensely between for instance Asian countries, Mediterranean 
countries and the United States, and yet these different studies are compared with each 
other. This makes meta-analysis a difficult issue, but still, there are at least five meta-
analyses performed in the last ten years trying to analyze whether or not eating red meat 
causes cancer (58-62). All of them are more cautious in their conclusions, producing 
lower OR estimates for the CRC risk in consumers of red meat above a certain level than 
the JAMA study cited above. OR estimates are in the meta-analyses (63) calculated to be 
in the range between 1.17 – 1.28 depending on study. There are studies claiming that the 
way of preparing and cooking the meat is more strongly associated with CRC risk than 
meat consumption per se (64, 65).
Introduction
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Carcinogenic compounds in food
There are many mutagenic substances believed to be present in food. Most of them are 
formed through reactions when the food is conserved or cooked (66). They belong to three 
main classes of compounds: heterocyclic amines (HCAs), polyaromatic hydrocarbons 
(PAHs) and N-nitroso compounds (NOCs).
HCAs are generated during high temperature cooking, like grilling, pan-frying and 
barbecuing, from the reaction between creatinine from the meat and muscular proteins 
and sugars in the meat. The amount of HCAs in the product is a function of cooking 
temperature and glucose or glycogen content of the meat, beef and chicken contain more 
HCAs than pork (67). Boiling and micro-wave cooking do not produce high enough 
temperatures to create HCAs (68, 69).
PAHs are formed by incomplete combustion of organic material and are ubiquitous 
contaminants in our environment. All kinds of organic compounds can create PAHs: 
fossil fuel, vegetable fuel, tobacco and food. They are inert, hydrophobic compounds 
that can be metabolized in mammal cells into metabolites capable of covalent binding 
to DNA, ultimately causing mutations and replication errors. In nonsmokers, the main 
source of human PAH intake is food which stands for 70%, the remainder comes from 
polluted air. Tobacco smoking adds about the same amounts in micrograms of PAH per 
day as food does. 
Several studies from different countries have investigated what kind of food is the main 
source of PAHs in an ordinary diet. In all of them, the major contribution was found to 
come from cereals, about 30%, and vegetable oils, also 30%. Vegetables and fruits and, 
to a lesser extent meat, contributes to the rest (70).  The PAH content in vegetables comes 
from air pollution. Fish and shellfish contain high levels of PAHs due to sedimentation 
of the molecules on the sea floor, and in meat, the PAH content is dependent on cooking 
method (70). There is a great inter individual variability in the sensitivity to PAHs. In 
a report by Maanen et al, the number of benzo[α]pyrene-DNA adducts was assessed in 
21 individuals who, after a period of abstinence from smoked or barbecued food, had 
to consume 170 g grilled hamburgers daily for 5 days. The PAH content in an index 
hamburger was measured by high performance liquid chromatography (HPLC). The 
characteristic DNA adducts were detected in mononuclear blood cells of 8 of the 21 
subjects. The experiment was repeated with a lower dose PAH as measured with HPLC in 
6 new subjects in the same manner. They saw no DNA adducts in the mononuclear cells 
in these subjects. This experiment indicates both a dose dependent potentially mutagenic 
effect of PAH and an inter individual difference in sensitivity (71).
NOCs are also carcinogenic because of their capacity to form DNA adducts. They appear 
in food mainly because of food preparations like curing and salting in order to prevent 
growth of bacteria like Clostridium botulinum (72). Exposure to NOCs can come from 
endogenous routes where high intake of red meat leads to elevated NOC levels in humans 
(73). NOCs can also originate from decarboxylation of amino acids by gut bacteria (72).
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Interactions between diet and low penetrance genes
As mentioned above, common polymorphisms in low penetrance genes can modify the 
risk of CRC from an environmental risk factor. 
In a recent review, Andersen et al had the ambition to review all prospective studies 
analyzing interactions between gene and diet. No such studies were found and they had to 
review large case-control studies instead (74). The review addressed interactions between 
genetic polymorphism and various dietary elements like meat, fish, fruit, fiber, vitamins 
and alcohol. ATP-binding cassette transporters, coded by the genes ABCB1, ABCC2 
and ABCG2, are proteins responsible for transport of fatty acids, bacterial products and 
dietary carcinogens in the bowel. Polymorphism in the ABCB1 gene was associated with 
CRC and meat intake in a dose dependent manner (75), although the authors cannot 
find a biological explanation since no difference in affinity for meat constituents was 
seen in an experimental model, making this epidemiological finding less reliable (74). 
Polymorphism in the gene coding for the pro inflammatory transcription factor NFκB 
was interacting with high meat intake and thus increasing risk for CRC. Significance 
level was borderline but experimental data support this finding. The authors conclude 
that a low anti-inflammatory response due to reduced synthesis of the p50 subunit of 
NFκB confers an increased CRC risk if the individual has a high dietary meat intake (74, 
76). Other gene-diet interactions were between GSTM1 and GSTT1 polymorphisms and 
fruit and vegetables and between low-activity variant of the anti-inflammatory cytokine 
interleukin 10 (IL10) and fiber intake, where the increased CRC risk seen in mutation 
carriers could be moderated by a high intake of dietary fiber (74).
The impact on CRC risk of polymorphisms in genes encoding various chytochrome P450 
proteins in relation to diet has also been investigated. This will be discussed in a section 
further below.
Development of CRC – molecular mechanisms
Genetics
The development from normal colonic epithelium to invasive cancer is a multistep 
process, often referred to as the adenoma-carcinoma sequence. The normal epithelium 
is polyclonal, arising from the colonic stem cells residing in the bottom of the epithelial 
crypts, while studies of the clonality of CRCs have revealed a monoclonal origin (77, 78).
Fearon and Vogelstein (77)  proposed a model for cancer development where a number 
of genetic and epigenetic alterations in one or a few initiating cells provide such growth 
advantages that it becomes the predominant cell. This process is named clonal expansion. 
One important initiating event in the adenoma – carcinoma sequence is a silencing 
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mutation or loss of the APC gene (77, 79). This gene has a silencing germ line mutation 
in FAP (see above), but is somatically mutated in most CRCs (80). Silencing of this gene 
activates the Wnt signaling pathway which involves stimulation of transcription factors 
regulating cell proliferation and migration properties (79). Other important events during 
the adenoma – carcinoma sequence are the activating mutations of RAS, which is seen in 
about 40% of CRCs, and BRAF, present in about 15% of CRCs (81-83). This stimulates 
cell proliferation.  At some point in tumor development, a random global demethylation 
of genes in the tumor cell occurs which in turn leads to transcription of normally silent 
oncogenes further promoting proliferation, and at the same time increased methylation 
of tumor suppressing genes result in enhanced cellular growth and proliferation (77). 
Mismatch repair genes can be silenced by methylation which is seen in patients with 
a microsatellite instable non-HNPCC associated tumor (79). Losses of chromosomal 
material and, secondary to this, silencing of the pro apoptotic gene TP53 is also often seen 
in CRC (77). Further mutations affect key pathways such as inactivating mutations in 
the tumor suppressor TGFBR2, present in about a third of CRCs (84, 85), and activating 
mutations in the proliferation stimulating PI3K gene, also present in one third of 
tumors (86). Numerous mutational events can also occur in genes normally maintaining 
chromosomal stability during DNA replication, resulting in chromosomal instability and 
aneuploidia (87).
These findings have been detected in tumors in the same frequency regardless of ethnicity 
of the patients, indicating that the same molecular mechanisms cause CRC notwithstanding 
varying hereditary factors and environmental exposures (88-91).
Parallel to the above mentioned genetic and epigenetic events, activation of various growth 
factor pathways is common. One example of this is the up-regulation of cyclooxygenase 
2 (COX-2), which induces synthesis of prostaglandin E2 (PGE2). This is believed to be 
caused by local inflammation or associated with mitogens (92). PGE2 has been associated 
with CRC, and COX-2 inhibitors, Aspirin and non-steroidal anti-inflammatory drugs have 
been shown to prevent the development of colorectal adenomas, and even to mediate 
regression of such adenomas (93, 94). The above described events are summarized in 
Figure 1.
The number of mutations in each tumor is both large and variable. Whole genome 
sequencing of CRCs from 11 patients revealed around 80 mutations resulting in altered 
amino acid sequence (95). Creation of a two-dimensional map of mutated genes visualized 
about half a dozen peaks – “mountains” – with previously well-known genes frequently 
mutated, and a large number of smaller “hills” with less frequently mutated genes. The 
most important mutations for driving malignant progression are by the authors thought 
to be those representing the “hills”. A large number of mutations, each one of which only 
confers a slight advantage, is probably what drives tumor progression, and the challenge 
is to find out what pathways are involved (95-97).      
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Figure 1. Genes and Growth Factor Pathways That Drive the Progression of Colorectal 
Cancer.
In the progression of colon cancer, genetic alterations target the genes that are identified 
at the top of the diagram. The microsatellite instability (MSI) pathway is initiated by 
mismatch-repair (MMR) gene mutation or by aberrant MLH1 methylation and is further 
associated with downstream mutations in TGFBR2 and BAX. Aberrant MLH1methyla-
tion and BRAF mutation are each associated with the serrated adenoma pathway. The 
question mark indicates that genetic or epigenetic changes specific to metastatic pro-
gression have not been identified. Key growth factor pathways that are altered during 
colon neoplasia are shown at the bottom of the diagram. CIN denotes chromosomal 
instability, EGFR epidermal growth factor receptor, 15-PGDH 15-prostaglandin dehy-
drogenase, and TGF-β transforming growth factor β.
Reproduced with permission from N Engl J Med 2009;361:2449-60, Copyright Massachusetts Medical 
Society.
Epigenetics
There is some evidence that epigenetic factors also play a role in tumor initiation and 
progression. Global demethylation can lead to chromosomal instability, and methylation 
can silence tumor suppressing genes as mentioned above (98). Other epigenetic events 
include histone modifications and loss of imprinting (LOI). Histone modifications enable 
the genomic DNA to be either silenced or activated by wrapping or un-wrapping the 
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chromatin. Imprinting is the normal silencing of one of the two parental copies of a certain 
gene, predominantly genes regulating cell growth and signaling. This phenomenon is seen 
in all mammalian cells. Loss of imprinting (LOI) means either activation of a normally 
silenced allele or silencing of a normally active allele (99). An example of this is the IGF2 
gene, where the activation of the normally inactivated maternal copy of the gene, LOI, 
is found in several different forms of malignancies like for example Wilm’s tumor, lung 
cancer, breast cancer and CRC (100-104). IGF2 has been shown in experimental models 
to have tumor promoting properties, generated by an autocrine self-feeding loop (105, 
106). Another epigenetic mechanism is when short non coding RNA fragments can bind 
selectively to certain promoter regions of the genome and silence that gene. These RNA 
fragments are called micro RNAs.
There are data supporting the idea of epigenetic alterations in normal tissue increasing 
the probability of tumor development when a mutation occurs. LOI of the IGF2 gene was 
found in 30% of CRC patients both in their tumor and in normal colonic mucosa, but only 
in 10% of healthy controls in a pilot study by Cui et al (107). Another investigation of 
LOI in an independent cohort of 172 patients undergoing colonoscopy for various reasons 
(age, gastrointestinal symptoms, family history of CRC), revealed a strong association 
between LOI in the colon and a family history of CRC. LOI was also detectable in 
lymphocytes from peripheral blood in 25 of the subjects and all of them had LOI also in 
the colon, and there was a concordance of LOI in right versus left colon in all subjects. 
The results were reproduced by another group and published by Woodson et al (103, 104). 
These data support the hypothesis of epigenetic alterations both preceding and promoting 
cancer development, and the issue in thoroughly reviewed by Fienberg et al (99).  There 
are suggestions that epigenetic changes occur primarily in colonic stem cells (99). The 
biology of colonic stem cells and their hypothesized role in CRC development will be 
discussed below.
Colonic stem cells and cancer
Stem cells are the progenitors to all different types of cells. There are embryonic stem 
cells giving rise to all various tissue types in the embryo, but there are also adult stem 
cells present in specific environments – niches - in specific tissue types in adult humans. 
These stem cells are organ specific, pluripotent and can differentiate into any of the cell 
types prevalent in the tissue. For example, the bowel mucosa consists of enterocytes - the 
mature epithelial cells-, goblet cells producing mucin, entero-endocrine cells producing 
gastrointestinal peptide hormones, Panteh cells being producers of antibacterial peptides, 
and less differentiated progenitor cells in the bottom of the colonic crypts giving rise to all 
the other cell types. There are also myofibroblasts in the stroma, closely interacting with 
the epithelial cells (108). 
The intestinal stem cells can divide symmetrically, giving rise to either two identical new 
stem cells or two identical daughter cells being a little bit more differentiated. Stem cells 
can also divide asymmetrically giving rise to one new stem cell and one more differentiated 
daughter cell that will start propagating up towards the top of the crypt. Symmetrical 
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division occurs in about 5% of the time, predominantly as a response to injury, while the 
asymmetric type takes place in about 95% of the time. This leads to monoclonality where 
one single stem cell will be dominating the crypt during a long period of time, in human 
colon estimated to be about 8 years, then there is a cyclic substitution of the stem cell 
dominance (108). The differentiation process and migration towards the top is believed 
to be made possible by gene expression gradients along the crypt axis. The different 
epithelial cell types and the gradients are depicted in Figure 2.
 The activation of the Wnt signaling pathway is high in the bottom of the crypt and 
decreasing towards the top while the bone morphogenetic proteins (BMP) signaling 
pathway is active in the top and decreasing towards the bottom. Just like Wnt signaling, the 
expression of the EphB receptor and the Ephrine-B trans-membrane ligands is distributed 
in a gradient where EphB mirrors the Wnt activity and Ephrine-B ligands the opposite 
(108). Wnt signaling is involved in maintaining stem cells by cell cycle control and 
inhibition of differentiation. It also controls migration along the crypt axis and terminal 
differentiation of Paneth cells. As mentioned above, mutations or epigenetic alterations 
affecting Wnt signaling are important events in carcinogenesis (109, 110). There are 
also interactions between the epithelium and the stroma where both Wnt signaling, BMP 
signaling, Hedgehog signaling and transforming growth factor β (TGFβ) are involved 
(111). 
The Eph receptors belong to a large tyrosine kinase receptor family and their membrane 
bound ligands are called ephrins. Their effects include cytoskeleton modulation 
which affects cellular motility and adhesion, and also cell survival, proliferation and 
differentiation (112). 
If a mutation or an epigenetic event causes activation of the Wnt pathway, EphB receptors 
are up-regulated in the affected cell. Expansion of these cells makes them bud out from 
the crypt and into the stroma forming large layers of transformed cells underneath the 
normal mature colonic epithelium as have been shown in animal experimental models 
(113, 114). During further tumor progression, the EphB receptor expression is often lost 
and this event then coincides with the invasion process (115, 116). 
Since tumor cells possess self-renewing properties, a typical stem cell feature, it has 
been postulated that cancers originate from a single mutated or epigenetically modified 
stem cell (117, 118). This suggestion is further supported by the fact that cancers can 
reoccur after several years of complete removal and remission. There are experiments 
where tumor cell lines consisting of a number of cellular phenotypes also contain a low 
proportion of cells with stem cell like properties. Only the stem cell like cells can give rise 
to a new tumor clone with all the phenotypic features of the original tumor clone when 
xenografted into an immunosuppressed mouse while none of the other cells in the clone 
have this ability (119, 120). In contrast to the single stem cell progenitor model, some 
studies suggest that during the process of invasion, made possible by transformation of 
the epithelial cell to acquire more mesenchymal traits, the invading cell becomes more 
stem cell like by this transformation. This process – epithelial to mesenchymal transition 
(EMT) will be described in more detail below. 
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Figure 2: Model for 2 types of intestinal stem cells. (A) Pictorial representation of crypt-villus structure 
in the small intestine. A gradient of BMP signaling, known to inhibit proliferation, is established along 
the crypt-villus axis, with relatively high activity throughout the villus and correspondingly less activity 
within the crypt. An opposite gradient of Wnt signaling, providing an important proliferative stimulus, 
is highest at the crypt base and decreases toward the crypt-villus junction. In addition a very restricted 
gradient of BMP antagonists originates from stromal cells near the crypt base and assists Wnt signaling 
in intestinal stem cells (ISCs). (B) An enlarged view of a small intestinal crypt depicting 2 different stem 
cell regions; a quiescent stem cell zone and an active stem cell zone. Position four label retaining cells 
(+4 LRCs) are normally maintained in a quiescent state through direct interaction with and signals gene-
rated from the niche, such as pericryptal myofibroblasts and adjacent enteroendocrine cells within the +4 
annulus. Crypt base columnar cells (CBCs), continually activated by signals generated from stromal cells 
at the crypt base, such as pericryptal myofibroblasts and smooth muscle cells, are responsible for most 
of the regenerative capacity of the intestine under homeostatic conditions. (C) Under various conditions 
of stress or injury, +4 LRCs may undergo transient activation to generate progenitors as well as CBCs. 
In addition, CBCs may be capable of regenerating lost +4 LRCs. Both intrinsic and extrinsic molecules 
known to associate with +4 LRCs, in both quiescent and transiently active states, as well as CBCs are 
listed.
Source: Gastroenterology 2008; 134:849-864 (DOI:10.1053/j.gastro.2008.01.079
Copyright © 2008 AGA Institute
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There are problems with the cancer stem cell model as well. One of the most significant 
problems with CRC stem cells is the lack of specific markers. Many cell surface proteins 
have been suggested, like CD133, CD44, Lgr5 and EpCAM , but none has been proven 
robustly expressed in all tumors examined since tumors display very varying phenotypes, 
probably also reflecting differences in their different stem cell populations. This makes 
them hard to study in all aspects (108, 121, 122). Other problems include the fact that the 
true frequency of cancer stem cells within a certain tumor is unclear, and probably also 
varies between tumors. The fact that many of the studies of cancer stem cells are performed 
on xenograft models also impose problems on translational relevance regarding their true 
behavior in patients (122).
Tumor stroma and inflammation
Tumor initiation, growth, invasion and metastasis are complicated events and a result 
of a complex interplay between genetic, epigenetic and environmental factors. Lots of 
attention has been paid to the malignant cell itself, but lately more attention also has 
been drawn towards the surrounding tissue – the stroma – and its role in promoting or 
repressing tumor growth, progression and invasion (123, 124). The cell types being most 
studied are tumor associated fibroblasts, immune cells and cells of the tumor vasculature. 
Tumor associated fibroblasts and immune cells will be discussed further. 
Tumor associated fibroblasts are believed to be derived from either myeloid progenitor 
cells from the bone marrow or from epithelial cells that have undergone transformation 
into mesenchymal-phenotype cells, a procedure called epithelial-mesenchymal transition 
(EMT) (124). When recruited from the myeloid precursor cells in the bone marrow, 
cytokines and chemokines from the tumor are thought to attract these cells to the tumor 
by similar mechanism as in physiological wound healing. The tumor stroma fibroblasts 
then can promote malignant behavior of the tumor cells by remodeling of the matrix 
proteins also present in the stroma, and by cross-talk with tumor cells, immune cells and 
vascular endothelial cells by secreting cytokines, chemokines and transcription factors. 
Remodeling of the matrix makes it easier for cancer cells to invade the surrounding tissue 
and, eventually, to metastasize (125, 126). An important pathway for maintenance of 
a tumor promoting phenotype of the tumor associated fibroblasts is the activation of 
NFκB which evokes a pro inflammatory response (127). A key cytokine believed to be 
an important promoter of tumor supporting inflammation  is interleukin 6 (IL-6), a target 
gene for NFκB, inducing production of the transcription factor signal transducer and 
activator of transcription 3 (STAT3) which further affect various immune cells present 
in the stroma (128). Other factors of importance for maintenance and regulation of stem 
cell properties of cancer stem cells and the properties of the supporting niche are soluble 
factors like Wnt, Notch, BMPs, hedgehog, epidermal growth factor (EGF), platelet 
derived growth factor (PDGF) and also hepatocyte growth factor (HGF) (129). There is 
also evidence for HGF promoting EMT and thus invasion and metastatic properties in the 
tumor (130, 131). 
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Immune cells are believed to have a dual role in tumors – they can be both tumor 
promoting and tumor suppressing depending on context. It is well established that chronic 
inflammation can lead to cancer, e.g inflammatory bowel disease can lead to CRC (132-
134). The tumor microenvironment of patients with no prior history of inflammatory 
disease is also often infiltrated by immune cells in varying quantities and in a varying 
state of activation. The inflammatory response is believed to be evoked by the genetic and 
epigenetic events in the tumor cells (135). The inflammatory cells present in the tumor 
stroma are mainly tumor associated macrophages and lymphocytes (135).
The human T-lymphocyte response to cancer can be either cytotoxic (Th1 response) leading 
to tumor suppression, or tolerance inducing (Th2 response) leading to tumor promotion. 
There are examples of both types of immune response to CRC. The molecular basis 
for this difference is different expression of cytokines, chemokines and growth factors. 
The reason for this is largely unknown although believed to be orchestrated by tumor 
associated macrophages present in the tumor stroma (135). Macrophages, fibroblasts 
and tumor cells can produce IL-6, IL-1β, COX-2 and IL-23. These induce expression 
of STAT3 and STAT5 which promote an immune-tolerant Th2 response that inhibits the 
cytotoxic T-cells and also promote further expression in the tumor microenvironment 
of pro-proliferative, pro-angiogenetic and anti-apoptotic factors (128).  A Th1 response, 
on the other hand, is evoked by production of IL-12, interferon gamma (IFN-γ), IFN-α 
and IFN-β from macrophages or other stroma cells, which in turn activate transcription 
of STAT1 and STAT4, two transcription factors having the opposite effect to those of 
STAT3. 
IL-6 also has systemic effects by stimulating the production of C-reactive protein (CRP) 
in the liver, creating a systemic inflammatory response which has been linked to a worse 
prognosis in CRC (136). Lymphocyte infiltration in the tumor is associated with a better 
outcome and is rarely seen in the IL-6/STAT3 dominated environment but more frequently 
in presence of a Th1 response (128, 137, 138). 
COX-2 is overexpressed in both tumor cells and tumor associated macrophages in about 
90% of CRCs (139-141). The induction of COX-2 in CRC is not fully understood although 
cytokines, growth factors and activated oncogenes probably are important inducers. 
The tumor promoting effect of COX-2 comes from both PGE2 dependent and PGE2 
independent pathways where the PGE2 dependent pathways include pro-proliferative, 
anti-apoptotic and motility stimulating actions. The PGE2 independent pathways include 
activation of pro carcinogens, e.g PAHs, and reduction of free arachidonic acid (AA) in 
the environment. AA has a pro apoptotic action (141).
Biology of the invasion – metastasis cascade
The process of invasion requires certain properties of the cell. A normal epithelial cell 
has a firm attachment to the neighboring cells, it has an apical-basal polarity and it has 
a cytoskeleton preserving a constant shape. In order to acquire invasive capacity, the 
cell must get rid of these features through the process called epithelial-mesenchymal 
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transition (EMT) described above (142). This process is induced by TGF-β produced 
by myeloid derived cells in the tumor stroma, or tyrosine kinase receptor ligands, that 
by up-regulation of transcriptional repressors like Snail, Slug, Zeb1, Zeb 2 and Twist 
inhibit expression of E-cadherin (143). The reduction of E-cadherin expression causes 
breakdown of intercellular junctions and induces Wnt signaling which further enhances 
the process resulting in loss of polarity and gain of motility (144). Tumor cells exhibiting 
these traits are mainly located in the invasion front of the tumor indicating the dependence 
of factors from the nearby stroma to obtain this specific phenotype. Cells in the core of the 
tumor do not as often have these features (145).
TGF-β has a dual role in tumor development – it can be both tumor suppressing and 
tumor promoting. The tumor suppression is mediated by initiation of a mothers against 
decapentaplegic 2/3/4 (SMAD2/3/4) complex, while the tumor promoting action is mediated 
by for example extracellular signal-regulated kinase (ERK) or phosphatidylinositol-3 
kinase (PI3K). The shift towards a more complete tumor promoting action of TGF-β is 
probably due to silencing or reduced levels of SMAD4 or to mutations in the TGFBR2 
gene (146-149).
The question why certain tumor cells can spread to and survive in a completely different 
organ with completely different prerequisites, and why they spread only to some organs 
but not to others, has interested scientists for centuries. In 1889, Stephan Paget asked the 
question: “What is it that decides what organs shall suffer in a case of disseminated cancer?” 
His own observations from autopsies of patients with fatal breast cancer contradicted the 
prevailing hypothesis that metastasis simply could be explained mechanistically, by the 
arrest of tumor cells in the capillary bed of an adjacent organ. He formulated the “seed 
and soil” hypothesis where the “seed” is the initiating cell or metastatic cell, and the 
“soil” is the microenvironment where the seed, aided by permissive factors in the soil, is 
able to settle down and sometimes to grow (150, 151). This hypothesis has survived over 
the centuries supported by many experimental and observational studies. One observation 
supporting this, is the fact that the drainage of malignant ascites in ovarian cancer into the 
vena cava does not result in massive metastasizing in spite of the fact that many grams 
of tumor cells must be shunted into the systemic circulation during that treatment (152). 
Specific organ preferences to specific tumor cells, regardless of vascular anatomy, have 
also been demonstrated in animal models (153).
In order to metastasize, the tumor cell – the “seed” - must be proficient in 10 different 
events. Each event is influenced by the interactions between the malignant cell and the 
stroma cells, growth factors, cytokines and chemokines in the surrounding tissue. First, 
the cell must be transformed into a neoplastic cell, and grow. When the tumor mass 
grows to more than 1-2 mm, angiogenesis is necessary for tumor survival. Local invasion 
of the host stroma and the capillaries is then imperative, made possible by the EMT 
process. Later on, the tumor cell aggregates must detach and enter the circulation. Well 
in the blood stream, a really harsh environment for metastasizing cells, the tumor cell 
aggregates must not only survive shear forces and lack of nutritional substrates, but also 
evade recognition and destruction by the host immune defense. The tumor cells must then 
arrest in the capillary bed of the target organ and successfully extravasate by mechanisms 
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similar to those involved in invasion. The next step is to survive and start to grow in the 
new site, the “soil”, establish vasculature, evade host immune response and eventually 
reinitiate a new metastatic process (154-156). Since most of our diagnostic methods 
have a detection limit of about 1 cm size, which means that the tumor has actually been 
growing for approximately 10-15 years, the metastasizing often already has occurred 
prior to diagnosis. Given the fact that metastatic cells, in many cases, can prevail for years 
in a state of dormancy in order to adapt to the new and sometimes hostile environment, 
the metastasis may not be detectable at the time of diagnosis of the primary tumor (154). 
The metastatic process is astonishingly inefficient – less than one in 10.000 tumor cells 
entering the blood stream ultimately form a macroscopic metastasis (156).
The seed can be characterized by examining either the circulating tumor cells (CTCs) 
from the blood stream or tumor cells from the metastatic lesions. A Spanish group has 
performed whole transcriptome analysis on isolated CTCs from 6 CRC patients revealing 
410 genes that characterized the CTC population not being expressed in blood cells from 
a control group of healthy subjects (157).  All these genes were related to cell movement 
and adhesion, cell proliferation and cell death, and cell signaling and interaction. These 
features are essential to a tumor cell clone in order to survive the metastatic process (157). 
The primary tumor displays a high degree of heterogeneity as to cellular phenotype. The 
phenotype of cells in a metastasis is also heterogeneous although less stable, probably 
due to increasing genetic instability in this selected, more malignant group of cells (154). 
The soil is believed to be prepared for the metastatic lesion by factors emanating from the 
primary tumor – the tumor cells, the stroma or both – attracting myeloid cells and, later, 
tumor cells to the metastatic site. This has led to the concept of a premetastatic niche. There 
is experimental data supporting this hypothesis where hematopoietic VEGFR1-positive 
cells from the bone marrow can arrive at a distant organ site to further promote homing 
of circulating tumor cells to that organ (158, 159). Another experimental study found that 
extracellular matrix from hepatocyte culture stimulated CRC cells more effectively to 
proliferate than did matrix from fibroblast culture (160).
Prognostic and predictive factors
As probably understood from what has been discussed above, CRC is a heterogenous, 
multi-pathway disease where we have few answers to what patients will respond to which 
treatment and why. In order to understand the reasons for treatment failure and to develop 
a tool to tailor the right therapy to the right patient, many groups have studied prognostic 
and predictive factors in CRC. Prognostic factors provide information about the natural 
course of disease while predictive factors address the question of benefit of treatment or 
not (161).
The most established prognostic factors are TNM stage and additional histopathological 
features including venous or lymphovascular invasion, free resection margins and tumor 
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grade (162-164). Tumor budding and tumor border configuration – pushing versus 
infiltrative – also seem to be of prognostic value although not yet used regularly in 
clinical practice. Absence of tumor budding is often associated with intra-tumoral or peri-
tumoral lymphocyte infiltrates which is associated with a better prognosis (165-169). 
Clinical features such as bowel obstruction, tumor perforation at presentation, somatic 
performance status and carcinoembryonic antigen levels, all of which probably most 
reflect the extent of tumor burden at diagnosis, independently affect outcome, although 
they do not predict response to treatment (163, 170, 171). There is an increasing interest 
in markers of systemic inflammation as prognostic factors in CRC. The rationale for 
this is the IL-6 driven vicious circle in the tumor microenvironment causing increased 
production of CRP in the liver and a systemic inflammatory response. This is believed to 
be detrimental due to both enhanced tumor growth and to increased drug toxicity (136, 
172). Preoperative CRP has not yet been formally included in the treatment planning 
algorithm.
Many molecular markers have been investigated with, to some extent, conflicting results. 
A good example for this is the KRAS mutation, present in about 30% of CRCs, where 
some reports have found it to be a prognostic factor while others have not (173-177). The 
reason why it is useful to know the mutational status of KRAS in a tumor, is that it predicts 
response to treatment with anti-EGFR antibodies, 99% of mutant carriers will not respond 
to such treatment (178). 
There are other common problems when evaluating potential prognostic or predictive 
markers apart from diverging results and lack of reproducibility. One is that many of the 
studies are performed on small samples, which often means lack of statistical power – i.e 
either the sample is too small to prove a true difference or you find a difference that is due 
just to chance but is interpreted as a true difference. Another problem is the inconsistent 
use of a wide array of methods in different studies making the studies hard to compare 
and impossible to draw any conclusions from performed meta-analyses (164).
The various molecular markers that have been analyzed include loss of the long arm 
of chromosome 18, APC mutation, TP53 mutation or loss, mismatch repair deficiency, 
chromosomal instability and differences in genetic polymorphism and gene expression 
levels in various enzymes taking part in the metabolism of chemotherapeutic agents (161). 
The enzymes mostly studied are thymidylate synthetase (TS) (179), dehydropyrimidine 
dehydrogenase (DPYD) (180, 181) and methylenetetrahydrofolate reductase (MTHFR) 
(182), all three of them involved in the metabolism of 5-fluorouracil (5-FU), a 
chemotherapeutic agent used in almost all treatment regimens for CRC. Polymorphisms 
in genes coding for enzymes important for the metabolism of oxaliplatin (e.g glutathione-
S-transferases) and irinotecan (UDP-gucurunosyltransferases) have also been evaluated. 
None of these have been proven robust enough to be included in the daily clinical practice 
or decision making due to reasons mentioned above (161).
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Cytochromes P450 – a family of enzymes
Cytochrome P450 (CYP) monooxygenases have important and diverse roles in both 
physiological and toxicological processes in vertebrates. Humans have 57 different active 
CYP genes (183) while for instance rice has 323 and mouse has 102. All CYP genes are 
believed to originate from one common ancestral gene some 2000 million years ago, 
branching out during evolution to the diversity between and within species that we see 
today (184).
The human CYP superfamily is divided into 18 families based on similarities in amino 
acid sequence: sequences being more than 40% identical belong to the same family (e.g 
CYP1, CYP2). The families are further divided into subfamilies having more than 55% 
identical amino acid sequences (e.g CYP2A, CYP2B) (185).
The CYPs are monooxygenases important in the phase I metabolism of for example foreign 
compounds, xenobiotics. Other examples of enzymes in this group are flavin-containing 
monooxygenases (FMOs), cyclooxygenases (COXs) and monoamine oxygenases (MAO). 
CYPs account for about 70% of phase I metabolism of xenobiotics in humans. The phase 
I reaction creates an intermediate metabolite which is further metabolized in a phase II 
reaction rendering it water soluble and possible to excrete in the urine. Examples of phase 
II enzymes are UDP-glucuronosyltransferases (UGTs), N-acetyltransferases (NATs) and 
glutathione S-transferases (GSTs). 
The CYPs typically catalyze a reaction where one atom of molecular oxygen is incorporated 
into the substrate and the other oxygen atom is reduced to water. This reaction requires 
also a reduction agent like for instance NADPH, and an agent to facilitate electron 
transfer, most commonly cytochrome P450 reductase. The cellular localization of CYPs 
in humans is mainly membrane bound in the plasma membrane or in the ER, and to a 
lesser extent in the mitochondria (186). 
CYPs are important enzymes in metabolism of both exogenous and endogenous 
compounds. Members of the families CYP1-3are mainly responsible for the metabolism 
of xenobiotics, CYP family 5-51 members are involved in the biosynthesis of endogenous 
substances and CYP family 4 members have a mixed function taking part in both 
metabolism of fatty acids, arachidonic acid and xenobiotics. Some family 1-3 members 
also have a function in vitamin D and arachidonic acid metabolisms (187). The main 
functions of the various human CYP families are displayed in Table 1. 
Most CYPs are expressed predominantly in the liver, although extrahepatic CYP expression 
is also seen. We are frequently exposed to various xenobiotics in the environment coming 
into contact with our skin, respiratory tract and gastrointestinal tract, and thus, these 
tissues express various CYPs to quickly take care of the first metabolic step.   
The human CYP5-51 family members are highly conserved throughout evolution and 
most of them have orthologs in fugu fish (Takifugu rubripes) (188). The CYP2 family 
is the most diverse with 16 genes and 11 subfamilies in humans and 42 genes and 11 
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subfamilies in zebrafish. There are a few CYP2 genes/subfamilies that are enough 
conserved to be considered orthologs, two of these are CYP2U1 and CYP2R1. They are 
found in all vertebrates examined so far, including birds and lizards. CYP2U1 functions 
in the hydroxylation of arachidonic acid and CYP2R1 acts as 25-hydroxylase of vitamin 
D2 and D3(189).
Polymorphism in the CYP genes
Many of the CYP genes are highly polymorphic. Detailed information is available at the 
website http://www.cypalleles.ki.se . The most polymorphic CYPs are those important to 
the metabolism of drugs, for example CYP2B6, CYP2C9, CYP2C19 and CYP2D6. This 
leads to inter-individual variations in the ability to metabolize drugs with ranges from 
poor metabolizers to ultrarapid metabolizers depending on polymorphism and homo- or 
hetero-zygosity (190). This in turn leads to large variations in sensitivity to toxic side 
effects of e.g anti-cancer drugs. CYP3A enzymes are important contributors to the 
metabolism of about 50% of all drugs on the market. CYP3A5 has a number of common 
and significant polymorphisms, although the consequences of these are less dramatic since 
the predominant CYP3A expression in adult life is the much more conserved CYP3A4 
(191, 192). 
The CYPs mainly metabolizing carcinogens are to a much lesser extent polymorphic with 
either rare or insignificant polymorphisms. Examples from this group of well conserved 
CYPs are CYP1A1, CYP1A2, CYP2E1 and the above mentioned CYP3A4, the latter 
taking part in metabolism of both drugs and pro-carcinogens (193). 
CYPs and cancer risk
The carcinogens mentioned previously, PAHs, HCAs and NOCs, can all be bioactivated 
by CYPs. CYP1A1, CYP1A2 and CYP1B1 are induced by these toxicants via the 
transcription factor aryl hydrocarbon receptor (AhR). AhR dimerizes with aromatic 
hydrocarbon receptor nuclear translocator (ARNT), also known as hypoxia inducible 
factor 1-β (HIF1B), and induce transcription of CYP genes (194, 195). No significant 
polymorphisms in these CYP genes have been found, although polymorphisms are seen 
in both AHR and ARNT. After the CYP catalyzed phase I reaction, the substance is further 
metabolized by phase II enzymes, e.g N-acyltransferases, where also polymorphisms are 
found (196). 
This complex regulation makes it difficult to prove simple correlations between various 
polymorphisms, diet and other life style factors due to reasons discussed earlier in the 
text. Briefly, it requires very large samples, strict control of confounding factors and a 
very stringent and reliable, ideally prospective, reporting of life style factors from the 
study subjects making such studies very hard to conduct. Numerous attempts have been 
made in order to evaluate genetic polymorphisms and association with environmental 
factors in cancer risk, the vast majority suffering from methodological weaknesses. There 
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are some well performed experimental studies in knockout mice indicating associations 
between CYPs and cancer risk due to pro-carcinogen activation, but the results from 
these studies, performed under extremely well controlled conditions, cannot be easily 
translated into patients (197, 198).
CYPs and prognosis
CYPs may theoretically affect outcome of cancer disease in two ways. One is tumor 
specific expression of CYPs contributing to either increased bio-activation of carcinogens 
further enhancing tumor growth or rapid elimination of anti-cancer drug in the tumor 
cells. Another way is ultra-rapid or slow metabolism of anti-cancer drugs in the liver 
leading to either reduced effect or toxic side effects. This may be due to inherited factors - 
polymorphisms – or factors related to the disease like for example systemic inflammation 
in cancer.
Tumor specific CYP expression is examined in several studies. CYP1B1, a metabolizer 
of pro-carcinogens, is frequently expressed in tumor tissue (193, 199). There are reports of 
CYP3A4 expression in breast cancer (200), osteosarcoma (201) and CRC. In one Spanish 
study analyzing CYP3A4 activity in CRC samples from 17 patients, the enzymatic activity 
of CYP3A4 towards paclitaxel was about one tenth of that in the liver (202). It should be 
mentioned, though, that CYP3A4 is also expressed in the normal colonic mucosa. Other 
CYPs found in CRC are CYP3A5, CYP2U1, CYP2S1, CYP2W1 and CYP51 (203-205).
CYP polymorphisms can also be important determinants of outcome due to variations in 
individual sensitivity to anti-cancer drugs. One example is CYP2D6, which displays an 
extensive genetic inter-individual variability resulting in defective or increased enzyme 
activity. CYP2D6 is involved in the metabolism of tamoxifen which has an impact on the 
response to tamoxifen therapy in breast cancer (193). Other relevant CYP polymorphisms 
are those in the CYP2C subfamily where for example CYP2C8 is involved in the 
metabolism of paclitaxel (193).
CYP2W1
The Human Genome Project (HUGO), started in 1989 and completed in 2003, revealed the 
existence of  a number of previously unknown CYP genes, CYP2R1, CYP2S1, CYP2U1, 
CYP2W1, and a number of CYP4 genes (206).
The CYP2W1 gene is a typical family 2-gene with 9 exons encoding a 490 amino acid long 
polypeptide. The human CYP2W1 gene is located on chromosome 7p22.3, and orthologs 
are found in other species, for instance birds, lizards, rat and mouse, although the gene 
is not as well conserved as CYP2U1  (207). Studies of expression of the gene have been 
performed showing high levels of CYP2W1 mRNA in samples from various human 
tumors, predominantly in colon and adrenal tumors, but not in any normal untransformed 
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tissue in samples from lung, placenta, liver, kidney, bowel, spleen, muscle, heart or brain 
apart from small trace amounts (207). In rat fetal tissues, the enzyme was expressed at the 
mRNA level in colon with increasing expression up to just before term. Western blotting 
of human tumors also showed protein expression in colon and, to a lesser extent, adrenal 
tumors (207). The function of the enzyme during fetal development is hitherto unknown.
Regulation of the CYP2W1 transcription
It is unclear what mechanisms are controlling the silencing of the CYP2W1 gene at term 
of gestation, and when in the sequential development from normal mucosa to invasive 
tumor the gene is activated. Gomez and coworkers analyzed methylation status of a CpG 
island in the exon 1-intron 1 junction. They found that the expression in CRC is associated 
with the demethylation of this CpG island, but concluded that there are probably other 
mechanisms influencing gene activation than just this single methylation site. The variable 
extent of expression between the cell lines examined, in spite of the same methylation 
status, indicate that other factors are involved as well, specific transcription factors or 
miRNAs for example. This remains to be elucidated (208). Maybe tumor hypoxia and 
HIF-1B plays a role for induction of CYP2W1 expression in combination with AhR 
induced by carcinogens in the diet. These are just speculations since we do not know if 
CYP2W1 expression is inducible by the AhR pathway.
Polymorphism in the CYP2W1 gene
Like for other members of the CYP family 2, polymorphisms in the CYP2W1 gene have 
been reported (209). Three of these are found in coding regions of the gene but only 
two of them give rise to changes in amino acid sequence. These two variant alleles are 
named CYP2W1*2 (Ala181Thr) and CYP2W1*6(Pro488Leu). Gervasini and coworkers 
published a study comprising 150 CRC patients and 263 controls that showed a decreased 
risk to develop CRC in carriers of the CYP2W1*2 allele (210). The plausible association 
between polymorphism in the CYP2W1gene and CRC risk is addressed in paper III of 
this thesis.
Substrates to CYP2W1
Investigations of potential substrates have been performed in various experimental models. 
Wu and coworkers found catalytic activity of CYP2W1 towards aflatoxin B1 and a number 
of other pro-carcinogens. They also found CYP2W1 to catalyze the N-demethylation of 
d-benzphetamine and, at a much slower rate, oxidation of arachidonic acid (211). Nishida 
et al found CYP2W1 to effectively activate the new anti-cancer agent AQ4N into a potent 
topoisomerase inhibitor in a hypoxic environment (212) and Tan et al found CYP2W1 
expression to be induced by another novel anti-tumor agent, GW-610, in a breast cancer 
cell line, and it also seemed as if CYP2W1 further activates the drug (213). Xiao and 
coworkers have shown that lysophopholipids – phospholipids where one acyl group has 
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been cleaved off - can be hydroxylated by CYP2W1, giving rise to the hypothesis that 
an imbalance between phospholipid metabolites may be a contributing factor for cancer 
development (214). A metabolite of lysophospholipids – lysophosphatidic acid – acts as 
a lipid mediator that stimulates proliferation and migration of cells. 
CYP2W1 has been proven to convert indole to oxindole (215) and in a recently published 
study to convert various duocarmycin analogues into metabolites, toxic or non-toxic 
depending on the substance used (216).
Using tumor specific CYP2W1 as a target for pro-drug activation
The pro-drug activation concept has already been tried for other CYPs expressed in tumors, 
although yet only at an experimental stage, targeting for example CYP1B1 (217, 218). 
The idea is that a non-toxic substance with selective specificity to the tumor specific CYP-
enzyme, is converted into a toxic metabolite killing selectively the tumor cell. Nishida 
and coworkers and Travica et al have explored this possibility by examining substrates 
converted by CYP2W1 to treat CRC with so far promising results in experimental models 
(212, 216). The duocarmycin analogues, indolines, investigated by Travica et al, are small 
molecules that fit into the active site of CYP2W1. The metabolite forms DNA adducts 
that cause cell death.
This conversion takes place in the endoplasmic reticulum (ER) of the cell where the largest 
proportion of CYP2W1 is abundant. About 8-10% is bound to the plasma membrane of 
the cell and could therefore be targeted by antibody treatment (219).
There are a few requirements for this model to work out. First, we must be sure the enzyme 
is tumor specific and not expressed in any normal tissue. Second, the substrate must have 
high affinity to one particular CYP enzyme. Third, the enzyme must be expressed in a 
fairly high amount of tumors and also in metastases. The enzyme also has to be expressed 
in an enough large amount of cells within a tumor, since tumors often are heterogeneous 
as previously discussed. It is unclear how large the minimum amount is. When one tumor 
cell dies, adjacent cells also die by what is referred to as the bystander effect. The impact 
of this in relation to CYP2W1 mediated toxicity is not yet fully elucidated although some 
proof of existence of the bystander effect in this particular reaction is revealed in the study 
by Travica et al (216). Last but not least, the enzyme must be catalytically active. 
If these requirements are fulfilled, targeted therapy using tumor specific CYP2W1 would 
be a novel complement to standard anti-cancer therapies.
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Aims of the thesis
The overall aim of this thesis is to explore the role of CYP2W1 in CRC.  
The more specific aims are:
To evaluate the extent of CYP2W1expression in primary CRC
To assess the association between CYP2W1 and tumor phenotype
To evaluate the relationship between polymorphism in the CYP2W1 gene 
and CRC risk
To evaluate the extent of CYP2W1 expression in colorectal metastases
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mAteriALs And methods
Patients
In study I and II, we used paraffin embedded blocks from patients with primary CRC 
stage II and III. The patients were derived from a randomized clinical Nordic trial aiming 
to evaluate surgical treatment compared to surgery combined with different adjuvant 
chemotherapy regimens. The original cohort consisted of 2224 patients under age 75 
years, that were treated for stage II and III CRC between 1991 and 1996. They were 
randomized to either surgery alone or to one of three plausible adjuvant treatment 
regimens: 5FU/levamisole for 12 months or 5FU/leucovurin for 4-5 months according to 
a Mayo clinic schedule with or without levamisole or a Nordic schedule with or without 
levamisole (220-222). From this large clinical trial, we obtained tumor specimen from 
162 patients with CRC treated at five different Swedish hospitals for study I and 235 
patients with colon cancer treated in 20 different hospitals for study II. Clinical data on 
patients and tumor characteristics were available, as were survival data. Tumor data were 
retrieved through the original pathology report while survival data were available through 
the regional centers of epidemiological oncology. Patient’s and tumor characteristics are 
summarized in table 2.  
In study IV, we used paraffin embedded tumor samples from patients having been treated 
for colorectal liver metastases at our unit for liver surgery between 2004 and 2009. The 
original population based cohort consisted of 255 patients that had undergone liver 
resections due to metastases from CRC. From this cohort, we could obtain samples from 
96 cases where also the primary tumor including lymph node metastases and all other 
metastatic manifestations having been resected, were available. The primary tumors were 
treated at 12 different hospitals between 1999 and 2009, the liver metastases were all 
operated at Karolinska University Hospital, Huddinge, and the lung metastases were all 
resected at Karolinska University Hospital, Solna. Patient’s and tumor characteristics 
and follow-up data were retrieved using patient’s records and the original pathology 
reports. These patients are also summarized in table 2 regarding demographics and tumor 
characteristics.
In study III, DNA preparations were obtained from 1785 patients with sporadic CRC 
and from 1761 healthy controls. The patients were treated between 2004 and 2006, and 
recruited from 14 different Swedish hospitals. Data were collected by the Department of 
Cancer Genetics at the Karolinska University Hospital, Solna, and the aim of the study was 
to assess risk loci for developing CRC (223). No data regarding tumor characteristics were 
used since the study aim was cancer risk assessment and not to study tumor phenotype. 
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The basis for the CRC diagnosis was the finding of invasive CRC in a colonoscopy 
sample, and patients were excluded if they had a family history of FAP or fulfilled the 
clinical Amsterdam criteria for HNPCC(223, 224). The control population consisted of 
1345 healthy blood donors from the general population, age between 18 and 65, and 416 
spouses of the cases, known to be cancer free by health examination, age between 25 and 
92. The age span of the cases was 27 – 95 years.
Study I: 
Number of patients 
(%)
Study II:
 Number of patients 
(%)
Study IV: 
Number of patients 
(%)
Total 162 235 96
Gender: Male 86 (53%) 127 (54%) 59 (61%)
                Female 76 (47%) 108 (46%) 37 (39%)
Age: Median 68 years 66 years 63 years
         Below median 82 (51%) 114 (49%) 42 (44%)
Stage at primary op: II 73 (45%) 103 (44%) 15 (16%)
                                     
III 89 (55%) 132 (56%) 25 (26%)
                                     
IV 0 0 56 (58%)
Tumor site: Colon 117 (72%) 235 (100%) 51 (53%)
                      Rectum 45 (28%) 0 45 (47%)
Tumor grade: Low 40 (25%) 58 (46%) 18 (19%)
                     Medium 117 (72%) 159 (67%) 74 (77%)
                         High 3 (2%) 14 (6%) 4 (4%)
                   Unknown 2 (1%) 3 (2%) 0
Primary tumor 
treatment:      
Surgery alone 81 (50%) 125 (53%) Not applicable
Surgery + adjuvant 81 (50%) 110 (47%) Not applicable
Number of lymph 
nodes  <12 92 (57%) 139 (59%) <13: 42
              ≥12          34 (21%) 17 (7%) ≥13: 54
              Unknown 36 (22%) 79 (34%) 0
               Range Unknown Unknown 3-50
Neoadjuvant 
treatment before 
primary op: No 145 (89%) 235 (100%) 47 (49%)
                      Yes 17 (11%) 0 49 (51%)
Chemotherapy before 
liver op: No Not applicable Not applicable 41 (43%)
                Yes Not applicable Not applicable 55(57%)
Table 2 Demographic and tumor related factors in the patients included in study I, II 
and IV
45
Immunofluorescence
In study I, II and IV, a polyclonal antibody towards the c-terminal of the CYP2W1 
protein was used. This antibody was developed by Karlgren and coworkers as previously 
described (207). In western blotting, this antibody has been proven superior to a whole-
protein antibody since it gives less background noise and non-specific bands.
In study I, this antibody was validated by immunofluorescence of cells from the human 
embryonic kidney cell line HEK-293 transfected with either a CYP2W1 containing 
plasmid vector or just the vector alone. After validation, this antibody was used in 
immunohistochemistry in study I, II and IV, and western blotting in study III.   
Immunohistochemistry
For the analysis of the tumor samples in study I, II and IV, we used immunohistochemistry 
(IHC). The same methodology was used in all three studies. We used the above described 
antibody in various dilutions; 1:1250 in study I, 1:1000 in study II and 1:2500 in study IV. 
The varying dilutions were decided after control staining of positive and negative control 
samples in order to get equally strong staining. 
The interpretation of the immune-staining was performed by two independent investigators 
with re-reading and consensus in case of disagreement. Disagreement occurred in less 
than 5% of cases. Since CYP2W1 is a protein to the largest extent abundant in the ER 
of the cell, and only to about 10% bound to the plasma membrane, staining was seen in 
the cytoplasm of the tumor cells. The staining intensity was graded from 0 to 3 where 
0 represented no staining, 1 weak staining, 2 moderate staining and 3 strong staining. 
The CYP2W1 staining was quite heterogeneously spread over the tumor slide, which 
necessitated a cut-off level for how large a proportion had to be stained in order to grade 
the slide. In study I and II, we stated that the strongest staining grade covering more than 
5% of the tumor area was the grade assigned to that slide. In study IV, the limit was raised 
to 10%. This will be discussed below. Examples of staining grades 0, 1, 2 and 3 in primary 
tumors are shown in fig 3.
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Polymerase chain reaction 
Polymerase chain reaction (PCR) is a powerful method to amplify DNA. Its advantage is 
when few genes in many samples are analyzed. If instead many genes in few samples are 
analyzed, then high throughput methods like Illumina sequencing are preferred. In study 
III, genetic polymorphism in the CYP2W1 gene was examined using two different PCR 
based genotyping methods.
Genomic DNA from the 1785 cases and the 1761control subjects, was kindly provided 
by professor Annika Lindblom, Department of Cancer Genetics, Karolinska University 
Hospital. The single nucleotide polymorphisms (SNPs) g2008G>A (Ala181Thr) (*2) and 
g5601C>T (Pro448Leu) (*6) were analyzed.
A lot of work had to be done in order to find out which available genotyping method was 
the most robust and most simple to perform since the number of samples was as large as 
roughly 3500 samples and two different loci. The CYP2W1*6 locus is particularly difficult 
to amplify due to the relative enrichment in C and G nucleotides. This difficulty is caused 
Figure 3. Examples of CYP2W1 staining intensities in samples of primary colorec-
tal tumors: grade 0, 1, 2 and 3.
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by the stronger hydrogen bonding between C and G nucleotides compared to those of 
T and A. After discarding the two methods High Resolution Melt and pyrosequencing 
because of too small ratio of interpretable results, the TaqMan® SNP genotyping assay 
and an allele specific real-time PCR method were proven to fulfill our criteria for a useful 
method. The Taqman assay was used for the CYP2W1*2 SNP and the allele specific assay 
for the CYP2W1*6 SNP. The Taqman assay, originally described by Heid and coworkers, 
is an allelic discrimination assay requiring a hybridization probe labeled with two 
different fluorescent dyes (225). Both alleles can be analyzed in one reaction requiring 
only one analysis per sample. For the *2 SNP, this method generated readable results in 
98% of cases, but used for the *6 SNP, the performance was unacceptably bad, probably 
due to the limited amount of DNA available in each sample. Instead, we used the above 
mentioned allele specific PCR method using SYBR Green, a fluorescent dye that binds to 
double stranded DNA. The dye – DNA complex absorbs blue light (λ=488 nm) and emits 
green light (λ=522 nm) which is then detected. The stringency of the PCR reaction is 
confirmed by melting curve analysis, an assessment of the dissociation characteristics of 
the double stranded PCR product during further heating. This melting curve interpretation 
is based on the fact that the hydrogen bonding between C and G is stronger than that of 
A and T.  For each sample, two analyses have to be made, one for each allele. This was 
the most robust and reliable method for the *6 SNP generating interpretable results in 
94% of cases. For internal validation, we re-ran 100 samples every 1000 samples, and 
random duplicates were blindly inserted in the first 800 samples. The concordance was 
good, >95%.     
cDNA constructs, transfections and cell viability assay
To evaluate functional activity of the enzymes expressed from the different genotypes, 
cDNA constructs must be created and, in a second step, transfected into cell lines. To 
start, the reference allele CYP2W1, labeled *1, was cloned into an expression vector 
generating a construct (pcDNA5/FRT/2W1*1). By a site-directed mutagenesis technique 
(QuikChange Lightning ®, Stratagene, La Jolla, California, USA), the SNPs – G541A 
(*2) and C1463T (*6) – could be generated in the *1 sequence, resulting in two new 
constructs (pcDNA5/FRT/2W1*2 and pcDNA5/FRT/2W1*6). The constructs were 
validated using DNA sequencing.
The above mentioned constructs were transfected into human colon cancer cell line 
SW480 in order to generate the variant proteins CYP2W1.1, CYP2W1.2 and CYP2W1.6. 
Control cells – mock transfected cells – were generated by transfecting SW480 cells 
with empty vector (pcDNA5/FRT). Protein expression in the cells was confirmed using 
western blot.
Cells were then seeded on plates in medium and incubated with substrate 
(chloromethylindolines ICT 2706 and ICT 2726) for 60 hours in triplicate. Cell viability 
was determined using EZ4U assay (Biomedica).
Materials and Methods
48
Kristina Stenstedt
CYP2W1 functional activity assay
Functional activity of the different variants of the CYP2W1 enzymes was assessed after 
incubation of the CYP2W1 transfected and the mock-transfected SW480 cells with the 
substrate ICT2726 for 4 hours. This indoline is known to be metabolized by CYP2W1 
into non-toxic metabolites. After incubation, the cells were harvested and centrifuged 
together with the medium in order to separate the cells from the medium. The cell pellet 
was suspended in acetonitrile and centrifuged once more at a higher speed. The two 
supernatants were mixed and, after another round of high speed centrifugation, analyzed 
by HPLC as previously described by Gomez and coworkers and by Travica and coworkers 
(216, 219). The substrate and metabolite peaks were monitored at 250 nm using Varian 
UV detector (Varian Inc., Palo Alto, California, USA).
Statistical Methods
Statistical analyses of the results of study I, II and IV were performed using STATISTICA 
software, release 10 (StatSoft®, Tulsa, Oklahoma, USA). In study III, Graph Pad Prism 5 
software package (La Jolla, California, USA) was used for all calculations.
In study I, II and IV, χ² test was performed to examine relationships between patient’s 
demographics, tumor characteristics and CYP2W1 expression. The Gehan Wilcoxon 
univariate test was used to evaluate the relationships between survival and patient’s 
demographics and tumor characteristics. Cox regression multivariate analysis was used 
in study I and II while in study IV, Cox’ proportional Hazard’s model was employed for 
this purpose. Survival analysis was performed using the Kaplan Meier method. In study 
II, Spearman Rank correlation test was performed for the assessment of correlation of 
CYP2W1 expression comparing two different slices from the same tumor.
All tests were two-tailed and considered significant at a p-value less than 0.05.  
In study III, the relationship between genotype and group – case or control – was examined 
using the χ² test. Results from the functional activity assay were compared using two-way 
ANOVA (Dunnett’s or Bonferroni) and data were expressed as means ±SD. All tests were 
considered significant at a p-value less than 0.05. 
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resuLts And disCussion
CYP2W1 expression in primary colorectal tumors
This aim was addressed in study I, II and IV. In study I, primary CRCs from 162 patients 
were analyzed by IHC with staining intensity graded 0 - 3 as explained above. 8% had no 
staining (0) while 18% exhibited grade 1, 38% grade 2 and 36% grade 3. The corresponding 
numbers from study II, where 235 patients with colonic cancer were evaluated, were 7% 
grade 0, 26% grade 1, 37% grade 2 and 30% grade 3. In study IV, 96 primary CRCs, the 
amount of high expressing tumors was slightly lower, 19% had grade 0, 30% grade 1, 
25% grade 2 and 26% grade 3. The number of patients in the different staining groups in 
the three studies is displayed in Table 3.
The IHC methods used in study I, II and IV were similar apart from the dilution of the 
antibody and the percentage required for a certain staining grade. The difference in 
percentage cut-off will be discussed in the section about metastases. The staining results 
in the primary tumors were fairly concordant. We used a method based on a combined 
scoring of staining intensity and proportion of stained to unstained cells. This method 
can be criticized for being subjective and with a high inter- and intra-observer variability. 
We have tried to avoid this as well as possible using the same investigators through the 
studies.
One problem with IHC described the literature is the lack of consensus regarding staining 
evaluation protocols. There are also differences in study design and other methodological 
problems making for example meta-analyses hard to conduct (164). It would be appropriate 
to validate the IHC findings using another method. We have not done this in our material, 
Number of patients 
Study I  n=162 (%)
Number of patients 
Study II  n=235 (%)
Number of patients  
Study IV  n=96 (%)
CYP2W1 staining 
grade 0 13 (8%) 16 (7%) 18 (19%)
CYP2W1 staining 
grade 1 29 (18%) 61 (26%) 29 (30%)
CYP2W1 staining 
grade 2 62 (38%) 87 (37%) 24 (25%)
CYP2W1 staining 
grade 3 58 (36%) 71 (30%) 25 (26%)
Table 3 CYP2W1 expression assessed by immunohistochemistry in primary colorectal tumors, 
study I, II and IV.
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simply because we only have access to formalin fixated, paraffin embedded tissue blocks 
from these particular primary tumors. However, CYP2W1 expression has been found in 
about 50% of CRC samples from another, although a lot smaller, patient material using 
western blot (207, 208). In another ongoing study, the amount of patients with strong 
CYP2W1 expression assessed with western blot is only 10% in the so far analyzed 50 
CRC samples (Johansson et al, unpublished data). This illustrates the need for validating 
studies in a larger cohort of patients.
The advantage of IHC is that the method is fairly easy to use, and also that samples from 
routine histopathology can be used. Another advantage is that an entire tumor slice can 
be analyzed in order to assess heterogeneities in expression, which might be missed using 
methods where only a small piece of the specimen is analyzed, e.g tissue microarray. 
Disadvantages with this method include the subjectivity in evaluation, the relatively low 
reproducibility and dependence of how the fixation process was conducted when the 
specimen originally was prepared for histopathology.
In study II, the question of tumor heterogeneity was also addressed. We could examine 
CYP2W1 expression in two slices from different parts of the same tumor in 107 patients 
with a correlation coefficient r=0.53, p<0.001. Within the same slice, though, the staining 
pattern is heterogenic with a tendency towards higher staining intensity near the invasion 
front (data not shown). 
CYP2W1 expression in primary tumor and relation to prognosis
Since a more malignant tumor phenotype often means a poor prognosis, we used 
survival as a proxy for tumor phenotype when addressing the second aim. In study I and 
II, we evaluated the association between CYP2W1 expression and prognosis. We also 
analyzed survival in study IV although this was not the primary aim of that study. High 
expression of CYP2W1, i.e grade 3, did not correlate to gender, age, stage, tumor site or 
differentiation in any of the studies except for study II where age correlated with high 
CYP2W1 expression.
In study I (n=162), no difference in survival was seen between patients with grade 0, 
1 or 2. Patients with grade 3 expression however, had a significantly worse outcome 
with both worse 5- and 10-year survival. High expression of CYP2W1 was found to 
be an independent prognostic factor in all patients in multivariate analysis (OR 1.4, 
[95% C.I 1.10-1.78], p=0.007). When analyzing colonic versus rectal cancer separately, 
CYP2W1expression did not fall out as a prognostic factor in rectal cancer (n=45), only in 
colonic cancer (n=117).
This was the rationale behind the analysis of colonic cancer only, and not CRC, in study 
II. The sample size in study II (n=235) was twice that of study I counting patients with 
colonic cancer. Since the result of the first study was highly significant, this sample size 
was assumed to be enough to ensure statistical power. Since grade 0, 1 and 2were of no 
significance in study I, we used the same classification with grade 3 versus the rest, for 
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the calculations in study II. However, high grade of CYP2W1 expression did not turn 
out to be of prognostic importance in the entire group of stage II and III colonic cancer 
patients. It did not reach significant level in univariate analysis although it fell out with 
borderline significance in multivariate analysis. High expression was of independent 
prognostic value in multivariate analysis of stage III patients only (n=132), OR 1.4, [95% 
C.I 1.12-1.75], p=0.003. The results of uni- and multivariate analyses of studies I and II 
are summarized in Table 4.
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It is not uncommon when analyzing new proteins as potential prognostic markers, that 
the initial study is very promising, but attempts at reproducing the results are not as 
successful due to reasons previously discussed (164). Validation in larger, independent 
cohorts, preferably using another method, is needed to further elucidate the prognostic 
value of CYP2W1. 
The fact that the study patients were treated for CRC so many years ago is also a 
problem when trying to assess various prognostic factors. During the early 1990’s, the 
importance of for example extensive lymph node sampling was not widely spread among 
the surgeons, which means that there is a risk for under-staging of the tumor disease. 
The total mesorectal/mesocolic excision concept and the cautious techniques discussed 
in the introduction of this thesis, were not as widely spread among surgeons. Today these 
methods are the golden standard in surgical treatment of CRC. This can of course also 
affect survival in the study patients. Another weakness of both study I and II is that the 
original pathology reports were used and the samples were not re-evaluated by a study 
pathologist. Some well-known risk factors for tumor spread and recurrence like vascular 
invasion are not even addressed in the pathology reports. This makes association, or lack 
of association, between CYP2W1 expression and tumor related factors, like grade, less 
reliable. 
One would assume that high expression of an enzyme normally expressed in fetal life 
would be associated with some kind of de-differentiation. This has not been evaluated in 
this study but would of course be of interest to investigate further. CYP2W1 expression 
might be just a result of random demethylation occurring during the adenoma-carcinoma 
sequence, and one plausible mechanism by which high expression of CYP2W1 could 
affect tumor phenotype, is by metabolizing pro-carcinogens into carcinogens, further 
enhancing tumor progression, as also discussed previously. These issues remain to be 
further elucidated. 
In study IV, CYP2W1 expression was not associated with outcome. Nor were demographic 
or tumor related factors like for example age, gender, primary tumor location, size and 
number of liver metastases, neo-adjuvant or adjuvant treatment or synchronous versus 
metachronous liver metastasis. In the entire population based cohort of 255 liver resected 
patients, from which our 96 patients were derived, only primary tumor location (rectum 
better than colon), presence of extra-hepatic metastases, involved microscopic resection 
margins and disease progression during chemotherapy were independent prognostic 
factors (Ydsten et al, unpublished data). Survival in the entire cohort was comparable to 
that of patients in studies from the best international centers, and did not differ from the 
5-year survival of our 96 study patients, indicating that our sample is not severely skewed.
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Polymorphism in the CYP2W1 gene and CRC risk
The third aim of this thesis was to elucidate the association between polymorphism in the 
CYP2W1 gene and risk to develop CRC. Why would it be of interest to analyze genetic 
variation in relation to CRC risk, when the gene is known to be expressed only in fetal life 
and in malignant tumors but not in normal colonic tissue?
CYP2W1 expression is so far only analyzed in tissue panels with various normal human 
tissues, in fetal rat tissues and in malignant tumors (207, 208). The expression has not yet 
been evaluated in for example polyps or colorectal adenomas. Hypothetically, expression 
in an early colorectal polyp of an enzyme that can activate pro-carcinogens may influence 
the risk of progression to a malignant tumor. This is one answer to that question. Another 
answer is that the association between CYP2W1 polymorphism and CRC has already been 
analyzed by Gervasini and coworkers, who found a protective effect of the CYP2W1*2 
SNP (210).
In study III, we aimed to elucidate this using a case-control approach, with an almost ten 
times larger group of patients and control subjects, and an experimental approach trying 
to evaluate the mechanism behind the presence or absence of such an association. The 
results of both these analyses were congruent – there was no difference in distribution 
of the various genotypes between cases and controls, and the different genotypes altered 
neither affinity, nor activity, towards a previously recognized substrate to CYP2W1 in our 
experimental model. The most natural interpretation of this is that CYP2W1 polymorphism 
is not a risk locus for CRC.
Objections to our results would point at the fact that the age distribution is slightly 
different between the cases and the controls, the control subjects being younger and less 
well described as a group. However, this study is designed to address genotype, which is 
a constant, unaffected by age. The control group is meant to be a representative sample 
from the background population from which the cases are derived and of a large enough 
size to rule out the risk of having too many young “potential cases” in the control group. 
We do not know the exact optimum size of the control group, though, and geneticists and 
epidemiologists often argue on this issue. The need of a very large sample size decreases 
if there is a plausible biologic explanation to the findings, as previously discussed. The 
enzyme activity assay in our study III provides such an explanation. 
      
CYP2W1 expression in colorectal metastases
The fourth aim was to analyze CYP2W1 expression in colorectal metastases. This was 
done in study IV where we analyzed CYP 2W1 expression in all tumor manifestations 
from 96 patients, i.e all primary tumors, all lymph node metastases, all liver metastases 
and all lung metastases. Our goal was to obtain tumor samples from all 255 patients in the 
population based cohort, but the logistical problems were overwhelming, partly since the 
Results and Discussion
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primary tumors were operated in 12 different centers and during a long time span. Yet, it is 
a large material compared with other groups comparing various differences in expression 
profiles between primary tumor and metastases from the same patient (226-228).
All 96 patients in study IV had undergone surgery for primary CRC and at least one liver 
resection. 27 had a second metastasis operation: 20 for new liver metastases, 6 for lung 
metastases and one for local recurrence. At primary surgery, 59 of the 96 patients had 
lymph node metastases. Calculations were performed on the primary tumor and the first 
liver metastasis. High expression of CYP2W1 did not correlate to demographic or tumor 
related factors, neither the expression in the primary tumor, nor in the liver metastasis. 
In the primary CRC, 26% had high CYP2W1 expression. Nodal metastases had high 
expression in 31% and in the first resected liver metastases, high expression was 
seen in 48%. Of the 20 patients that underwent a second liver operation, 10 had high 
CYP2W1expression, 9 had low expression and one had no tumor left in the specimen. In 
the lung metastases (n=6), 2 had high CYP2W1 expression and 4 had low expression. The 
amount of liver metastasis with high CYP2W1 expression was significantly higher than 
the primary tumors (48% versus 26%, p=0.005). In figure 4, the dynamics of CYP2W1 
expression in primary tumor versus liver metastasis is schematically described.
The IHC method used in study IV did not differ from that in study I and II apart from the 
dilution of the antibody and that the assessment of grade was slightly stricter. In study I 
and II, the grade of the slide was defined as the strongest grade that covered at least 5% 
of the slide, while we in study IV required 10%. This reflects the aim of our investigation 
of metastases, which is more directed towards a potential treatment pathway rather than 
just find enzyme expression. Higher amount of high CYP2W1expressing cells now 
seemed to be more important, although the arbitrary cut-off at 10% could be discussed. 
As previously mentioned, we do not know the extent of the bystander effect when it 
comes to cytotoxicity of the CYP2W1 derived metabolites. The higher cut-off- level of 
10% used in study IV could also explain the slightly higher percentages in the weaker 
staining groups in this study compared with study I and II.
An illustration of slightly heterogeneous staining in a liver metastasis is shown in figure 
5. 
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Figure 4. The dynamics of CYP2W1 expression in colorectal primary tumors and liver metastases
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As also applied to the investigations of the primary tumors in study I and II, validation of 
CYP2W1 expression in liver metastases is of great importance. 
The reason why CYP2W1 expression seems to increase in the metastases is of course 
something we just may speculate about. Our study is, although small in sample size, 
comparatively large when going through the literature. Habermann and coworkers have 
analyzed transcriptomes and proteomes in tissue samples from 20 primary colorectal 
tumors and 13 liver metastases, and only in 2 cases the primary tumor and the metastasis 
came from the same patient (226). The full array comprised some 9000 cDNAs and 
revealed 158 genes to be differently expressed between primary tumor and metastasis. 
From the proteome analyses, expression levels of 32 proteins were found to be increased 
in the metastases compared to the primary tumors. From an omics-study like that, it is hard 
to draw any conclusions about the expression of a single protein. Conversely, it is also 
difficult to make any statements on changes in expression patterns in general just studying 
one single protein. The biology of tumor and metastases is more complicated than that, 
and depends largely on random events and genomic instability (154, 157). Maybe high 
expression of CYP2W1 co-varies with other factors that provide survival benefits for the 
tumor cell in the metastatic process, or maybe it is simply an effect of the random genetic 
and epigenetic events occurring in the invasion – metastasis cascade. 
From the results of our study, it seems as if expression of CYP2W1 is increased in 
colorectal liver metastases, and if this finding is reproducible, it adds an interesting 
perspective when searching for novel pathways in the treatment of metastatic CRC.
Figure 5. Example of slightly heterogenous staining in a colorectal liver metastasis, overall 
interpreted as grade 2.
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ConCLusions
In summary, the conclusions of this thesis are
CYP2W1 is expressed at high levels in about 30% of primary human colorectal tumors 
assessed by immunohistochemistry. Expression assessed with another method would be 
of interest.
High CYP2W1 expression in the primary tumor is associated with poor survival. This 
needs to be confirmed in a larger, independent patient material.
There is no association between polymorphisms CYP2W1*2 or CYP2W1*6 and risk to 
develop CRC. Neither are there any functional differences between the corresponding 
gene products.
CYP2W1 protein is expressed in 48% of colorectal liver metastases assessed by 
immunohistochemistry. The expression in metastases is significantly higher than in the 
primary tumors. Validation using another method is of importance.  
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future PersPeCtives
The most interesting aspect of CYP2W1 expression in CRC and metastases is not whether 
or not it is an independent prognostic factor. What is the most exciting part is the prospect 
of drug development. As previously mentioned, the need of validation is imperative, 
especially in this perspective. We hope to be able to start doing this using fresh frozen 
material from the same liver metastases as already have been investigated by IHC in 
study IV. The planned method of analysis is liquid chromatography-mass spectrometry 
(LC-MS).
The prerequisite for pro-drug activation in the patient is of course a functional enzyme 
expressed in the tumor. CYP2W1 expressed by transfected CRC cell lines is functional 
but it is of importance also to find out whether the CYP2W1 present in the tumor samples 
from patients has a good catalytic activity. There is an ongoing prospective study aiming 
to address this question using fresh material from patients undergoing surgery for primary 
CRC. In order to assess CYP2W1 expression, these tumors are analyzed with western 
blot and histopathologic slides from their tumors could be analyzed by IHC also in order 
to validate the method. Functional activity in the CYP2W1 expressing tumors will be 
analyzed using the duocarmycin substrates and the assay described in the study by Travica 
et al (216).    
We are also planning to start using fresh material from patients being operated for 
colorectal liver metastases in order to assess functional activity. This project has some 
logistic problems that have to be solved before it can start since the liver operations are 
performed in Huddinge and our laboratory is in Solna.
The question when in the development from normal epithelium to invasive cancer the 
CYP2W1 gene is activated remains to be answered. An important study would be to 
investigate either CYP2W1 expression by IHC or CYP2W1 gene methylation by bisulfide 
sequencing in colorectal adenomas of various size and degrees of dysplasia.
The increased CYP2W1 expression in metastases and the fact that the only normal, 
non-malignant, expression is during fetal life, raises the question whether CYP2W1 
is expressed in stem cells or stem cell like cells. This is of course speculative, but an 
interesting question to find out more about. One problem is, as discussed previously, 
the lack of reliable stem cell markers for colorectal stem cells. When this area becomes 
more developed, it would be of interest to find out if CYP2W1 expression in any way 
is associated with stem-ness of the tumor cells, not least because of the perspective of 
killing cancer stem cells with a pro-drug.  
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The biological function of CYP2W1 in fetal life is unknown. A CYP2W1-/- knockout 
mouse model is under development where the aim is to study the phenotype and presence 
of any malformations.
There are some more thrilling questions also lacking answer. For example how the 
extremely reactive metabolite to the duocarmycin analogue physically can migrate from 
the ER to the nucleus to form the DNA adducts? How large is the bystander effect and 
what are the mechanisms behind it?
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PoPuLärvetenskAPLiG 
sAmmAnfAttninG På svenskA
Cancer är den näst vanligaste dödsorsaken i Sverige efter hjärt-kärlsjukdom. Tjock- och 
ändtarmscancer, kolorektalcancer (CRC) är den näst vanligaste cancerformen hos kvinnor 
och den tredje vanligaste hos män både i Sverige och globalt. Man vet att det finns rent 
ärftliga former av CRC. Dessa är emellertid inte så vanliga utan står bara för ungefär 3-4 
% av alla CRC fall i Sverige. Hos de andra har ärftliga faktorer också betydelse men inte 
på ett lika enkelt och tydligt sätt. Man tror att små genetiska skillnader i kombination med 
faktorer i miljön, t ex kost, har betydelse för vilken risk man har att utveckla cancer och 
hur cancersjukdomen sedan beter sig när den väl har brutit ut.
Om man drabbas av CRC är det viktigt att man kan operera bort tumören. Ibland behöver 
man tilläggsbehandling med strålning och cellgifter. Man vet också att prognosen är bättre 
om sjukdomen upptäcks tidigt. Man kan även operera bort dottertumörer – metastaser 
– om de finns i begränsad omfattning. Ofta behövs då också cellgiftbehandling som 
komplement. Om man kan operera bort alla metastaser är prognosen bättre än i de fall där 
detta inte är möjligt. Det är angeläget att hitta nya sätt att angripa cancern och utveckla 
nya typer av läkemedel, särskilt när sjukdomen börjat sprida sig, eftersom det är dessa 
patienter som idag har sämst prognos, även med bästa tillgängliga behandling.
I kroppen finns en familj med enzymer, cytokrom P-450- familjen (CYP), som utgör 
förutsättningen för en mängd livsviktiga kemiska reaktioner. Ett sådant exempel är t ex 
CYP21 som är nödvändigt för att kunna tillverka cortisol, ett stresshormon som man inte 
kan klara sig utan. Ett annat exempel är CYP3A4 som behövs i nedbrytningen av väldigt 
många av de läkemedel som finns på marknaden. Det finns CYP-enzymer som bryter ner 
giftiga substanser i vår miljö som vi utsätts för. I vissa fall blir dessa substanser ännu mera 
giftiga av den reaktion som CYP bidrar med, men då bryts de ner vidare av andra – fas 
II-enzymer – och kan sedan utsöndras från kroppen via urinen. Både växter och djur har 
CYP-enzymer, människan har 57 olika CYP, ris har 323.
Av de 57 CYP-enzymerna hos människa, har 13 en mer eller mindre okänd funktion. Ett 
sådant har fått beteckningen CYP2W1. Det enzymet har visat sig inte finnas i levern, som 
väldigt många av de andra CYP-enzymerna gör, utan i tjocktarmen under fosterstadiet 
hos råtta, och i människa finns det inte alls eller bara i mycket små, försumbara mängder 
i normala vävnader i kroppen. Däremot har man hittat enzymet i olika cancertumörer, 
främst i CRC. I den här avhandlingen har vi studerat förekomsten av CYP2W1 i dels 
vävnadsprover från cancertumörer i tjocktarmen och ändtarmen – primärtumörer - och 
dels från metastaser i lymfkörtlar, lever och lungor. Det är dels med syfte att kartlägga i hur 
stor andel av CRC som CYP2W1 finns och dels för att se om detta påverkar överlevnaden. 
Vi har också frågat oss om medfödda olikheter i genen som kodar för just CYP2W1 är 
förenat med ökad eller minskad risk för att drabbas av CRC. 
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Vi kom fram till att CYP2W1 uttrycks i ca 25-30% av alla primärtumörer, i 30% av 
lymfkörtelmetastaser och i nästan hälften , 48%, av alla levermetastaser. Det finns visst 
fog för påståendet att starkt uttryck av CYP2W1 i primärtumören är associerat med en 
sämre prognos men man behöver titta mera på det i ytterligare, större studier för att vara 
säker. Det är ingen ökad eller minskad risk att drabbas av CRC om man har någon av de 
två genetiska förändringar vi har studerat. Funktionen hos enzymet var dessutom likadan 
oavsett hur genuppsättningen såg ut när vi testade detta i en experimentell modell.
Kunskaperna vi fått från studierna i denna avhandling är att det förefaller finnas 
CYP2W1-utryck i ca en tredjedel av alla primärtumörer och troligen i en högre andel av 
levermetastaser. Eventuellt är dessa tumörer också lite ilsknare än andra. Man skulle i 
framtiden kunna utnyttja att CYP2W1 finns i tumörer och metastaser genom att man ger 
en ofarlig substans till patienten som sedan i själva tumörcellen omvandlas av CYP2W1 
till en giftig substans. Eftersom CYP2W1 inte finns i normal vävnad, skulle tumörcellen 
dödas men inte den friska vävnaden. Djurförsök har visat att detta är möjligt, även om det 
är en lång väg kvar innan det blir ett färdigt läkemedel som kan ges till patienter.          
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